Austin J Peters1, Laura E Villasana, Eric Schnell. 1. From the Department of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, Oregon (A.J.P., L.E.V., E.S.) the Anesthesiology Service, Veterans Affairs Portland Health Care System, Portland, Oregon (E.S.).
Abstract
WHAT WE ALREADY KNOW ABOUT THIS TOPIC: WHAT THIS ARTICLE TELLS US THAT IS NEW: BACKGROUND: : Traumatic brain injury induces cellular proliferation in the hippocampus, which generates new neurons and glial cells during recovery. This process is regulated by N-methyl-D-aspartate-type glutamate receptors, which are inhibited by ketamine. The authors hypothesized that ketamine treatment after traumatic brain injury would reduce hippocampal cell proliferation, leading to worse behavioral outcomes in mice. METHODS: Traumatic brain injury was induced in mice using a controlled cortical impact injury, after which mice (N = 118) received either ketamine or vehicle systemically for 1 week. The authors utilized immunohistochemical assays to evaluate neuronal, astroglial, and microglial cell proliferation and survival 3 days, 2 weeks, and 6 weeks postintervention. The Morris water maze reversal task was used to assess cognitive recovery. RESULTS: Ketamine dramatically increased microglial proliferation in the granule cell layer of the hippocampus 3 days after injury (injury + vehicle, 2,800 ± 2,700 cells/mm, n = 4; injury + ketamine, 11,200 ± 6,600 cells/mm, n = 6; P = 0.012). Ketamine treatment also prevented the production of astrocytes 2 weeks after injury (sham + vehicle, 2,400 ± 3,200 cells/mm, n = 13; injury + vehicle, 10,500 ± 11,300 cells/mm, n = 12; P = 0.013 vs. sham + vehicle; sham + ketamine, 3,500 ± 4,900 cells/mm, n = 14; injury + ketamine, 4,800 ± 3,000 cells/mm, n = 13; P = 0.955 vs. sham + ketamine). Independent of injury, ketamine temporarily reduced neurogenesis (vehicle-exposed, 105,100 ± 66,700, cells/mm, n = 25; ketamine-exposed, 74,300 ± 29,200 cells/mm, n = 27; P = 0.031). Ketamine administration improved performance in the Morris water maze reversal test after injury, but had no effect on performance in sham-treated mice. CONCLUSIONS: Ketamine alters hippocampal cell proliferation after traumatic brain injury. Surprisingly, these changes were associated with improvement in a neurogenesis-related behavioral recall task, suggesting a possible benefit from ketamine administration after traumatic brain injury in mice. Future studies are needed to determine generalizability and mechanism.
WHAT WE ALREADY KNOW ABOUT THIS TOPIC: WHAT THIS ARTICLE TELLS US THAT IS NEW: BACKGROUND: : Traumatic brain injury induces cellular proliferation in the hippocampus, which generates new neurons and glial cells during recovery. This process is regulated by N-methyl-D-aspartate-type glutamate receptors, which are inhibited by ketamine. The authors hypothesized that ketamine treatment after traumatic brain injury would reduce hippocampal cell proliferation, leading to worse behavioral outcomes in mice. METHODS:Traumatic brain injury was induced in mice using a controlled cortical impact injury, after which mice (N = 118) received either ketamine or vehicle systemically for 1 week. The authors utilized immunohistochemical assays to evaluate neuronal, astroglial, and microglial cell proliferation and survival 3 days, 2 weeks, and 6 weeks postintervention. The Morris water maze reversal task was used to assess cognitive recovery. RESULTS:Ketamine dramatically increased microglial proliferation in the granule cell layer of the hippocampus 3 days after injury (injury + vehicle, 2,800 ± 2,700 cells/mm, n = 4; injury + ketamine, 11,200 ± 6,600 cells/mm, n = 6; P = 0.012). Ketamine treatment also prevented the production of astrocytes 2 weeks after injury (sham + vehicle, 2,400 ± 3,200 cells/mm, n = 13; injury + vehicle, 10,500 ± 11,300 cells/mm, n = 12; P = 0.013 vs. sham + vehicle; sham + ketamine, 3,500 ± 4,900 cells/mm, n = 14; injury + ketamine, 4,800 ± 3,000 cells/mm, n = 13; P = 0.955 vs. sham + ketamine). Independent of injury, ketamine temporarily reduced neurogenesis (vehicle-exposed, 105,100 ± 66,700, cells/mm, n = 25; ketamine-exposed, 74,300 ± 29,200 cells/mm, n = 27; P = 0.031). Ketamine administration improved performance in the Morris water maze reversal test after injury, but had no effect on performance in sham-treated mice. CONCLUSIONS:Ketamine alters hippocampal cell proliferation after traumatic brain injury. Surprisingly, these changes were associated with improvement in a neurogenesis-related behavioral recall task, suggesting a possible benefit from ketamine administration after traumatic brain injury in mice. Future studies are needed to determine generalizability and mechanism.
Authors: Simona Gradari; Paloma Pérez-Domper; Ray G Butler; Carmen Martínez-Cué; Gonzalo G de Polavieja; José Luis Trejo Journal: Hippocampus Date: 2016-02-09 Impact factor: 3.899
Authors: Alexandre G Dayer; Abigail A Ford; Kathryn M Cleaver; Mina Yassaee; Heather A Cameron Journal: J Comp Neurol Date: 2003-06-09 Impact factor: 3.215
Authors: Daniel H Arndt; Jason T Lerner; Joyce H Matsumoto; Andranik Madikians; Sue Yudovin; Hannah Valino; David L McArthur; Joyce Y Wu; Michelle Leung; Farzad Buxey; Conrad Szeliga; Michele Van Hirtum-Das; Raman Sankar; Amy Brooks-Kayal; Christopher C Giza Journal: Epilepsia Date: 2013-09-13 Impact factor: 5.864
Authors: Lyles R Clark; Sanghee Yun; Nana K Acquah; Priya L Kumar; Hannah E Metheny; Rikley C C Paixao; Akivas S Cohen; Amelia J Eisch Journal: Front Neurosci Date: 2021-01-07 Impact factor: 4.677
Authors: Thiago G Bassi; Elizabeth C Rohrs; Karl C Fernandez; Marlena Ornowska; Michelle Nicholas; Matt Gani; Doug Evans; Steven C Reynolds Journal: Sci Rep Date: 2021-03-03 Impact factor: 4.379
Authors: Faleh Alqahtani; Mohammed A Assiri; Mohamed Mohany; Imran Imran; Sana Javaid; Muhammad Fawad Rasool; Waleed Shakeel; Farzane Sivandzade; Ahmed Z Alanazi; Salim S Al-Rejaie; Musaad A Alshammari; Fawaz Alasmari; Mohammed Mufadhe Alanazi; Faisal F Alamri Journal: Biomed Res Int Date: 2020-12-10 Impact factor: 3.411
Authors: Erica L Littlejohn; Anthony J DeSana; Hannah C Williams; Rudy T Chapman; Binoy Joseph; Jelena A Juras; Kathryn E Saatman Journal: Front Cell Dev Biol Date: 2021-05-20